Japanese Phase 1 Trial of Sym004 in Solid Tumors

NCT01955473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Sym004

Sponsor

Merck KGaA, Darmstadt, Germany